Alzheimer Disease: AAN Diagnosis, Biomarker Workup, and Anti-Amyloid Therapy
A clinical guide to Alzheimer disease that integrates DSM-5 major neurocognitive disorder criteria, the AT(N) biomarker framework with CSF and amyloid PET, cholinesterase inhibitor and memantine therapy, and the new anti-amyloid monoclonal antibodies lecanemab and donanemab with ARIA monitoring.
Executive Summary
Alzheimer disease (AD) is the most common cause of dementia, accounting for 60–80% of cases, and now affects more than 55 million people worldwide. The 2018 NIA-AA Research Framework reframed AD as a biological construct defined by amyloid (A) and tau (T) biomarkers with neurodegeneration (N) modifying severity—the AT(N) framework—rather than by clinical syndrome alone. Diagnosis proceeds through structured cognitive testing (MoCA with score ≤25 of 30 suggesting impairment, MMSE for staging), DSM-5 criteria for major or mild neurocognitive disorder, exclusion of reversible causes (B12, thyroid, depression), structural imaging with MRI to exclude vascular and structural disease, and—when amyloid-targeted therapy is being considered—biomarker confirmation with amyloid PET, CSF Aβ42 / Aβ42:Aβ40 ratio with elevated p-tau and t-tau, or the new plasma p-tau217 assay (which approaches PET-level accuracy). Symptomatic therapy combines cholinesterase inhibitors (donepezil 5–10 mg PO daily, rivastigmine 4.6–13.3 mg/24 h patch, galantamine 8–24 mg PO daily ER) for mild-to-moderate disease and adds memantine 5–20 mg PO daily for moderate-to-severe disease. The disease-modifying anti-amyloid monoclonal antibodies lecanemab 10 mg/kg IV q2 wk (2023 FDA approval) and donanemab 700 mg IV q4 wk × 3, then 1400 mg q4 wk (2024 FDA approval) modestly slow cognitive decline in early symptomatic AD with biomarker-confirmed amyloid pathology, but require ApoE4 genotyping and serial MRI surveillance for amyloid-related imaging abnormalities (ARIA-E and ARIA-H)—the principal treatment-limiting toxicity, especially in ApoE4 homozygotes.
1. Definition, Epidemiology, and AT(N) Framework
Alzheimer disease is a progressive neurodegenerative disorder pathologically defined by extracellular β-amyloid (Aβ) plaques and intracellular hyperphosphorylated tau neurofibrillary tangles, with secondary synaptic loss, neuronal death, and gliosis. Clinically it presents most commonly as an amnestic syndrome with progressive impairment of episodic memory and executive function, but atypical presentations include posterior cortical atrophy (visuospatial dysfunction), logopenic primary progressive aphasia, and frontal/dysexecutive variants. Global prevalence is rising rapidly with population aging—an estimated 55 million people live with dementia worldwide, projected to triple by 2050. AD accounts for 60–80% of cases, with vascular cognitive impairment, dementia with Lewy bodies, frontotemporal dementia, and mixed pathology comprising the remainder.
The DSM-5 reframed dementia as major neurocognitive disorder (NCD) when one or more cognitive domains (complex attention, executive function, learning and memory, language, perceptual-motor, social cognition) show significant decline that interferes with independence in daily activities, and as mild NCD (corresponding to mild cognitive impairment, MCI) when decline is modest and does not interfere with independence. AD-specific etiology requires evidence of memory and learning impairment plus a steadily progressive cognitive decline, with no other neurologic, psychiatric, or systemic explanation; biomarker confirmation strengthens the diagnosis.
The NIA-AA 2018 Research Framework shifted the operational definition of AD from a clinical-pathological construct to a biological construct defined by biomarkers grouped into three categories: A (amyloid—amyloid PET or CSF Aβ42 / Aβ42:Aβ40 ratio), T (tau—tau PET or CSF p-tau), and N (neurodegeneration—FDG-PET, MRI atrophy, or CSF t-tau). This AT(N) framework classifies individuals as A+T+ (Alzheimer continuum), A+T− (Alzheimer pathologic change), or A−T+ (suspected non-Alzheimer pathology), allowing biomarker-confirmed diagnosis even in cognitively unimpaired individuals (preclinical AD) and informing eligibility for disease-modifying therapy.
Major Risk Factors
| Category | Factor | Magnitude / Note |
|---|---|---|
| Non-modifiable | Age | Doubles every 5 years after 65 |
| Non-modifiable | ApoE4 allele | Heterozygote ~3× risk; homozygote ~12× risk |
| Non-modifiable | Family history / autosomal dominant (PSEN1, PSEN2, APP) | Early-onset (<65) AD; rare (~1%) |
| Non-modifiable | Down syndrome (trisomy 21) | Almost universal AD pathology by 5th–6th decade |
| Modifiable | Hypertension, diabetes, dyslipidemia, obesity, smoking, sedentary lifestyle | Lancet Commission: 14 modifiable factors account for ~45% of dementia risk |
| Modifiable | Hearing loss (untreated), social isolation, depression, low education, alcohol >21 units/wk | Lifestyle counseling and treatment recommended |
2. Cognitive Assessment and Differential Diagnosis
Clinical evaluation begins with a structured history obtained from both the patient and an informant, since insight is often impaired. The history should establish duration, onset (insidious vs abrupt), pattern (gradually progressive vs stepwise vs fluctuating), specific cognitive deficits (memory, language, visuospatial, executive), behavioral changes, functional decline (instrumental and basic activities of daily living using IADL/ADL scales), medication review, and family history of dementia or autosomal dominant AD. Neurologic examination targets focal deficits (suggesting vascular dementia or stroke), parkinsonism (DLB, PSP, CBS), gait abnormalities (NPH, vascular), and primitive reflexes (advanced disease).
Standardized Cognitive Tests
| Test | Time | Threshold for Impairment | Strengths |
|---|---|---|---|
| Mini-Cog | 3 min | 0–2 of 5 (3-word recall + clock draw) | Brief screen in primary care |
| MoCA (Montreal) | 10 min | ≤25 of 30 (add 1 point if ≤12 yrs education) | More sensitive for MCI than MMSE; preferred |
| MMSE (Folstein) | 10 min | ≤24 of 30 (mild 21–26, moderate 11–20, severe ≤10) | Standard staging; insensitive for MCI |
| SLUMS | 10 min | ≤19 (HS+) or ≤20 (less) | Better detects MCI than MMSE; VA standard |
| ACE-III | 20 min | ≤82 of 100 | Domain-specific subscores; useful for FTD |
The 2018 AAN guideline strongly recommends evaluating for reversible causes with: TSH, vitamin B12 (and methylmalonic acid if borderline), CBC, CMP (calcium, glucose, electrolytes, hepatic and renal function), and structural imaging (brain MRI preferred over CT) to exclude tumor, subdural hematoma, normal pressure hydrocephalus (gait disturbance + urinary incontinence + cognitive impairment with ventricular enlargement out of proportion to atrophy), and large-vessel infarcts. Targeted testing includes RPR/VDRL when syphilis risk factors are present and HIV testing in selected cases. Routine EEG is not indicated; lumbar puncture is reserved for suspected normal pressure hydrocephalus, CNS infection, or AD biomarker workup.
Differential Diagnosis of Dementia
| Disorder | Distinguishing Features | Imaging / Biomarker |
|---|---|---|
| Vascular cognitive impairment | Stepwise decline, focal deficits, vascular risk factors | MRI: lacunar infarcts, white matter hyperintensities |
| Dementia with Lewy bodies (DLB) | Visual hallucinations, REM sleep behavior disorder, parkinsonism, fluctuating cognition | DAT-SPECT abnormal; polysomnography for RBD |
| Frontotemporal dementia (bvFTD) | Behavioral disinhibition, apathy, executive dysfunction, age <65 | MRI: frontal/temporal atrophy; FDG-PET frontal hypometabolism |
| Primary progressive aphasia | Progressive language impairment (semantic, nonfluent, logopenic variants) | MRI: left perisylvian or anterior temporal atrophy |
| Normal pressure hydrocephalus | Gait + cognitive + urinary triad; large CSF tap improves gait | MRI: ventriculomegaly out of proportion to atrophy |
| Creutzfeldt-Jakob disease | Rapidly progressive (weeks–months), myoclonus, ataxia | MRI: cortical ribboning + basal ganglia DWI; CSF RT-QuIC; EEG periodic complexes |
| Pseudodementia (depression) | Subacute onset, “I don’t know” answers, mood symptoms | Improves with antidepressant trial |
3. Biomarker Workup: CSF, Amyloid PET, and Plasma p-tau217
Biomarker testing is now central to AD diagnosis when (1) atypical clinical presentation, (2) early-onset disease (<65 years), (3) MCI with diagnostic uncertainty, or (4) candidacy for anti-amyloid therapy. The three principal modalities target the same underlying pathology with different operational characteristics.
| Biomarker | What it Measures | AD Pattern | Notes |
|---|---|---|---|
| CSF Aβ42 / Aβ42:Aβ40 ratio | Soluble amyloid in CSF | ↓ Aβ42; ↓ Aβ42:Aβ40 (more specific) | Bedside; pairs with tau in same sample |
| CSF total tau and p-tau181 | Tau in CSF | ↑ both; p-tau more specific for AD | Distinguishes AD from FTD, DLB |
| Amyloid PET (florbetapir, florbetaben, flutemetamol) | Brain amyloid plaque burden | Diffuse cortical retention | Centiloid scale; expensive; high accuracy |
| Tau PET (flortaucipir) | Brain tau tangle burden | Medial temporal → cortical spread | Correlates with severity; donanemab trial used to stage |
| FDG-PET | Cerebral glucose metabolism | Bilateral temporoparietal hypometabolism | Differentiates AD from FTD (frontal hypometabolism) |
| Plasma p-tau217 | Phosphorylated tau in blood | Markedly elevated (>cutoff) | Newest; approaches amyloid PET accuracy; FDA-cleared assays available 2024–2025 |
| MRI volumetry | Hippocampal/entorhinal atrophy | Bilateral hippocampal atrophy | Supportive; insensitive for early AD |
Practical Biomarker Sequencing
For most patients with suspected AD seeking biomarker confirmation: start with plasma p-tau217 if available (least invasive, lowest cost). If positive and clinically actionable, proceed to confirmatory amyloid PET or CSF testing prior to initiating anti-amyloid antibody therapy because reimbursement and label requirements typically require amyloid PET or CSF confirmation. CSF is preferred when both amyloid and tau status are needed in a single sample, when MRI is contraindicated, or when cost favors lumbar puncture.
4. Symptomatic Pharmacotherapy
Pharmacotherapy for AD divides into symptomatic agents (cholinesterase inhibitors and the NMDA antagonist memantine) that modestly improve cognition and global function without altering disease trajectory, and disease-modifying agents (anti-amyloid monoclonal antibodies; see Section 5). Symptomatic therapy is offered to most patients with mild-to-severe AD; the decision balances modest functional benefit (effect size approximately equivalent to delaying decline by 6 months) against gastrointestinal and cardiovascular adverse effects.
Cholinesterase Inhibitors
| Drug | Indication / Stage | Dose | Notes |
|---|---|---|---|
| Donepezil (Aricept) | Mild–severe AD | 5 mg PO daily × 4–6 wk → 10 mg daily; consider 23 mg for moderate–severe | QHS dosing; most common; vivid dreams a clue |
| Rivastigmine (Exelon) | Mild–moderate AD; PD dementia | 1.5 mg PO BID → titrate q4 wk to 6 mg BID; or patch 4.6 → 9.5 → 13.3 mg/24 h | Patch reduces GI AEs vs PO; rotate site daily |
| Galantamine (Razadyne) | Mild–moderate AD | 8 mg ER daily × 4 wk → 16 → 24 mg daily | Take with morning meal; nicotinic modulation in addition to AChE inhibition |
All cholinesterase inhibitors share a class effect of cholinergic adverse events: nausea, vomiting, diarrhea, anorexia, weight loss, vivid dreams, urinary frequency, muscle cramps, and—of particular concern—vagally mediated bradycardia, syncope, and AV block. Avoid in symptomatic bradycardia, sick sinus syndrome, second- or third-degree heart block (without pacemaker), active peptic ulcer disease, severe hepatic impairment, and uncontrolled asthma. Co-prescription with non-dihydropyridine calcium channel blockers, beta-blockers, or other bradycardic agents requires caution and ECG/HR monitoring. Always titrate from the starting dose to minimize GI intolerance, and assess effect at 6 months; do not abruptly discontinue—cognitive decline can accelerate.
NMDA Receptor Antagonist: Memantine
- Memantine (Namenda): 5 mg PO daily × 1 wk → titrate weekly by 5 mg → 10 mg PO BID (or 28 mg ER daily). Renal dose: 5 mg PO BID if CrCl 5–29 mL/min.
- Indication: Moderate-to-severe AD (MMSE ≤14–18) as monotherapy or in combination with a cholinesterase inhibitor (Namzaric: donepezil + memantine combination).
- Adverse effects: Generally well tolerated; dizziness, headache, confusion, constipation; urinary alkalinization (sodium bicarbonate, carbonic anhydrase inhibitors) increases plasma levels.
Behavioral and Psychological Symptoms of Dementia (BPSD)
FDA Black Box: Antipsychotics in Dementia-Related Psychosis
All atypical and typical antipsychotics carry an FDA black box warning of increased mortality when used to treat dementia-related behavioral disturbances (NNH ≈ 87 for death over 10 weeks). They are not first-line therapy. First, identify and treat reversible triggers (pain, infection, constipation, urinary retention, environmental change, medication adverse effect). Implement nonpharmacologic strategies (structured routines, music therapy, validation, redirection, caregiver education). When pharmacotherapy is unavoidable for severe agitation or psychosis with risk of harm to self or others, brexpiprazole (the only FDA-approved agent for AD agitation, 2023) 0.5 mg PO daily titrated to 2–3 mg daily is preferred, with risperidone or quetiapine as alternatives at the lowest effective dose for the shortest possible duration with quarterly reassessment for taper.
- Depression: SSRIs (sertraline, citalopram ≤20 mg/day in elderly) are first-line; avoid TCAs (anticholinergic burden).
- Apathy: Cholinesterase inhibitor optimization; consider methylphenidate in selected cases.
- Sleep disturbance: Sleep hygiene; trazodone 25–100 mg PO QHS; avoid benzodiazepines and Z-drugs.
- Agitation/aggression: Brexpiprazole, risperidone, citalopram (limited evidence).
5. Anti-Amyloid Monoclonal Antibodies and ARIA
The anti-amyloid monoclonal antibodies (mAbs) lecanemab (Leqembi, full FDA approval July 2023) and donanemab (Kisunla, FDA approval July 2024) are the first disease-modifying therapies for AD with confirmatory efficacy in phase 3 trials. Both reduce cerebral amyloid burden by 60–80% on PET and slow clinical decline by approximately 25–35% on the CDR-Sum of Boxes (CDR-SB) over 18 months in early symptomatic AD (MCI or mild dementia stage) with biomarker-confirmed amyloid pathology. Treatment effect is modest in absolute terms (CLARITY-AD: 0.45 CDR-SB difference at 18 months) but represents a paradigm shift toward targeting the underlying biology.
Indications and Eligibility
- Clinical syndrome of MCI due to AD or mild AD dementia (MMSE ≥22 or equivalent)
- Confirmed amyloid pathology by amyloid PET or CSF Aβ42 / Aβ42:Aβ40 + p-tau (label requirement)
- ApoE4 genotyping required before initiation (FDA boxed warning)—homozygotes have markedly increased ARIA risk
- Baseline brain MRI within 12 months excluding >4 microhemorrhages, prior macrohemorrhage, superficial siderosis, vasogenic edema, or severe leukoaraiosis
- Patients on therapeutic anticoagulation are generally excluded due to ARIA-H bleeding risk
Dosing and Monitoring
| Drug | Dose | Schedule | MRI Surveillance |
|---|---|---|---|
| Lecanemab (Leqembi) | 10 mg/kg IV over ~1 hr | Every 2 weeks indefinitely | Baseline + before infusions 5, 7, 14 (~22, 26, 52 wk) |
| Donanemab (Kisunla) | 700 mg IV q4 wk × 3 → 1400 mg IV q4 wk | Every 4 weeks; consider stopping when amyloid PET-negative (TRAILBLAZER design) | Baseline + before infusions 2, 3, 4, 7 |
Amyloid-Related Imaging Abnormalities (ARIA)
The principal treatment-limiting toxicity is amyloid-related imaging abnormalities (ARIA), with two patterns: ARIA-E (vasogenic edema, sulcal effusion on FLAIR) and ARIA-H (microhemorrhages or superficial siderosis on T2*/SWI). ARIA most commonly emerges within the first 3–6 months of therapy, is most often asymptomatic, and is detected on protocol surveillance MRI. Symptomatic ARIA presents with headache, confusion, dizziness, visual disturbance, nausea, or—rarely but most concerning—seizures and encephalopathy.
| Subgroup | ARIA-E rate (lecanemab) | ARIA-H rate |
|---|---|---|
| ApoE4 non-carrier | ~5% | ~12% |
| ApoE4 heterozygote | ~11% | ~14% |
| ApoE4 homozygote | ~32–35% | ~39% |
ARIA Management Protocol
Asymptomatic mild ARIA-E or ≤4 new microhemorrhages: continue therapy with closer MRI monitoring. Symptomatic ARIA, moderate-to-severe ARIA-E, or >10 new microhemorrhages, any macrohemorrhage, or superficial siderosis: hold therapy, repeat MRI in 4 weeks, treat severe symptoms with corticosteroids (high-dose IV methylprednisolone) at clinician discretion (no controlled-trial evidence). Permanent discontinuation is required for moderate or severe symptomatic ARIA-E that does not resolve, recurrent ARIA, macrohemorrhage, or superficial siderosis. Avoid t-PA in patients on lecanemab/donanemab presenting with stroke (case-fatal hemorrhage reported).
Practice Insights: AD — ATN Biomarker Framework, Lecanemab Era, and APOE-Stratified ARIA Monitoring
(The content below synthesizes published clinical patterns and expert consensus rather than first-person case reports.)Anti-amyloid therapy turns an Alzheimer diagnosis into an eligibility question, and eligibility cannot be answered by clinical impression alone — (1) NIA-AA ATN biomarker framework (amyloid + tau + neurodegeneration) is the diagnostic standard; CSF or plasma biomarkers replace gestalt-based diagnosis; (2) lecanemab and donanemab anti-amyloid therapy is offered to eligible MCI/mild AD patients with confirmed amyloid positivity; (3) APOE genotyping stratifies ARIA risk and is non-negotiable before anti-amyloid initiation. The “treat with donepezil and wait for progression” approach has been retired in favor of biomarker-confirmed early intervention with disease-modifying therapy.
NIA-AA ATN biomarker framework — diagnosis at the cellular level
The 2018 NIA-AA biomarker framework defines AD pathophysiology by A (amyloid), T (tau), and N (neurodegeneration) markers — independent of clinical symptoms. A+T+ confirms AD pathology regardless of cognitive status. Available markers: CSF Aβ42/40 ratio + p-tau (gold standard); amyloid PET + tau PET (anatomic but expensive); plasma p-tau 217 (emerging, less invasive, increasingly accurate). For MCI or mild dementia, experienced clinicians obtain CSF biomarkers or plasma p-tau 217 to confirm AD pathology before considering anti-amyloid therapy. MRI assesses neurodegeneration (hippocampal atrophy) and rules out alternative causes (NPH, vascular, tumor, subdural).
Lecanemab / donanemab for confirmed amyloid + MCI/mild AD
Lecanemab (Leqembi, FDA Jan 2023) is a monoclonal antibody against soluble Aβ protofibrils — 10 mg/kg IV q2 weeks. CLARITY-AD: 27% slower cognitive decline at 18 months in MCI or mild AD with confirmed amyloid positivity. Donanemab (Kisunla, FDA July 2024) targets amyloid plaques; limited-duration treatment until amyloid clearance achieved. Eligibility: confirmed amyloid (CSF or PET), MCI or mild AD (CDR 0.5-1.0, MMSE generally > 22), no anticoagulation contraindication, no significant cerebrovascular disease. Seasoned clinicians offer anti-amyloid therapy to all eligible patients — the disease-modifying benefit is real and the natural history without intervention is grim.
APOE genotyping stratifies ARIA risk — non-negotiable before anti-amyloid
Amyloid-related imaging abnormalities (ARIA) are the major adverse event of anti-amyloid therapy. ARIA-E (vasogenic edema): 13% overall; ARIA-H (microhemorrhages): 17% overall — both stratified strongly by APOE ε4 carrier status. APOE ε4 homozygotes have ~35% ARIA-E incidence; heterozygotes ~10-15%; non-carriers ~5-8%. Experienced practitioners obtain APOE genotype before anti-amyloid initiation. Homozygotes warrant careful counseling about elevated risk; some centers exclude them entirely. MRI surveillance schedule: baseline + before doses 5, 7, 14 (more frequent if APOE ε4 carrier or ARIA history). Symptomatic ARIA pauses or discontinues therapy.
Symptomatic therapy continues: donepezil + memantine + BPSD management
Anti-amyloid therapy does not replace symptomatic treatment. Cholinesterase inhibitor (donepezil 5-10 mg daily preferred for tolerability; rivastigmine 4.6-9.5 mg/24h patch for GI intolerance) provides modest cognitive/functional benefit. Memantine 5-20 mg daily added for moderate-severe disease (MMSE < 15). Behavioral and psychological symptoms (BPSD): non-pharmacological first (environment, routine, caregiver education); SSRIs for depression/anxiety; brexpiprazole (FDA-approved 2023) or low-dose risperidone for severe agitation only, with FDA black-box warning for increased mortality. Caregiver support resources and advance directives discussed at diagnosis — not after crisis.
Anonymized Case: Mild AD with Lecanemab Initiation and ARIA-E Management
A man in his late sixties presented with his wife after 18 months of gradual short-term memory decline, word-finding difficulty, and one instance of getting lost while driving. Cognitive testing: MMSE 22/30, MoCA 18/30 (impaired recall and visuospatial function). Neurological exam normal. MRI brain: bilateral mesial temporal atrophy, no significant white-matter disease, no microhemorrhages. CSF analysis: Aβ42/40 ratio reduced (0.05; normal > 0.075), p-tau elevated (110 pg/mL; normal < 60), total tau elevated (650 pg/mL) — A+T+N+ profile confirming AD pathology. Plasma p-tau 217 also elevated (consistent). APOE genotype: ε3/ε4 (heterozygous — intermediate ARIA risk). Diagnosis: Mild AD dementia, biomarker-confirmed. Initiated donepezil 5 mg, titrated to 10 mg over 4 weeks. Counseling provided about lecanemab risks and benefits; patient and wife elected to proceed. Lecanemab 10 mg/kg IV q2 weeks initiated. Baseline MRI clean. At month 4 (after dose 7), surveillance MRI showed asymptomatic ARIA-E in the right parietal lobe (small focal edema, no clinical symptoms). Lecanemab paused 2 weeks per protocol; repeat MRI showed resolution. Resumed lecanemab without further ARIA. Cognitive testing at 12 months: MMSE 21, MoCA 17 — minimal decline (typical untreated trajectory would be 2-3 point decline per year). Caregiver support resources engaged; advance directives completed early in the trajectory.
Four Protocol Deviations Experienced Clinicians Now Default To
- NIA-AA ATN biomarker confirmation before AD diagnosis label. CSF Aβ42/40 + p-tau (gold standard), amyloid PET, or plasma p-tau 217 (emerging). A+T+ confirms AD pathology. MRI for neurodegeneration + rule out alternatives (NPH, vascular, tumor). Gestalt-based diagnosis retired.
- Lecanemab or donanemab anti-amyloid therapy for confirmed amyloid + MCI/mild AD. Lecanemab 10 mg/kg IV q2 weeks (CLARITY-AD 27% slower decline at 18 mo). Donanemab limited-duration until amyloid clearance. Offer to all eligible — disease-modifying benefit real.
- APOE genotyping before anti-amyloid initiation — stratifies ARIA risk. ε4 homozygotes ~35% ARIA-E (counseling intensive or exclude); heterozygotes ~10-15%; non-carriers ~5-8%. MRI surveillance baseline + before doses 5, 7, 14 (more frequent for APOE ε4). Asymptomatic ARIA pauses; symptomatic discontinues.
- Symptomatic therapy (donepezil + memantine) continues alongside anti-amyloid + BPSD non-pharmacological first. Brexpiprazole or low-dose risperidone for severe agitation only (FDA black-box mortality). SSRIs for depression. Caregiver support + advance directives at diagnosis — not after crisis.
6. Care Planning, Special Populations, and Pearls
Comprehensive Care Beyond Medications
- Driving evaluation—formal road test once moderate stage (MMSE 18–22) is reached or family raises concern.
- Advance care planning early—health care proxy, living will, code status, surrogate decision-maker.
- Caregiver support—Alzheimer’s Association referral, respite care, education, depression screening for caregiver.
- Falls prevention—remove rugs, install grab bars, treat orthostatic hypotension, vitamin D, exercise programs.
- Vaccinations—influenza, pneumococcal, RSV, shingles per age-based recommendations.
- Lifestyle—Mediterranean or MIND diet, regular aerobic exercise, social and cognitive engagement, hearing aids if indicated, treatment of hypertension and diabetes.
When to Refer to Neurology, Geriatric Psychiatry, or Memory Clinic
Refer to a memory clinic, neurologist, or geriatric psychiatrist when: (1) early-onset (<65) cognitive decline; (2) atypical presentation (rapid progression, focal cortical syndromes, prominent behavioral or movement features); (3) diagnostic uncertainty after first-pass workup; (4) consideration of anti-amyloid antibody therapy or amyloid PET; (5) refractory BPSD requiring complex psychotropic management; (6) suspected reversible cause (NPH, autoimmune encephalitis); or (7) family request for confirmation of diagnosis. Early specialist involvement supports diagnostic accuracy, biomarker access, anti-amyloid eligibility decisions, and family education.
Pearls and Pitfalls
Pearl: ApoE4 testing before lecanemab
ApoE4 homozygotes have approximately 35% ARIA-E rates and increased symptomatic and serious ARIA risk. Discuss expected risk explicitly with the patient and family before initiating anti-amyloid therapy and document shared decision-making. Some specialists offer a slower titration or alternative agent for homozygotes.
Pitfall: Antipsychotics for sundowning
Reaching for quetiapine or risperidone before searching for treatable triggers (UTI, pain, fecal impaction, polypharmacy, environmental change) increases mortality without addressing the cause. Identify and treat triggers; reserve antipsychotics for severe, dangerous behaviors when nonpharmacologic measures and SSRIs have failed.
Pearl: MoCA outperforms MMSE for MCI
The MoCA detects mild cognitive impairment at higher sensitivity than the MMSE, particularly for executive dysfunction and visuospatial tasks. Use MoCA as the first-line bedside cognitive instrument and MMSE for serial staging once major NCD is established.
Pitfall: Stopping cholinesterase inhibitors abruptly
Discontinuation of cholinesterase inhibitors—particularly donepezil—can be followed by accelerated cognitive and functional decline that does not always reverse on rechallenge. Taper rather than stop, and reserve discontinuation for clear intolerance, terminal phase, or shared decision after honest review of net benefit.
Frequently Asked Questions
What cognitive screen should I use in primary care?
Which reversible causes of cognitive decline should I screen for?
When should I order biomarker testing for Alzheimer disease?
How effective are cholinesterase inhibitors?
When is memantine indicated?
Who is a candidate for lecanemab or donanemab?
What is ARIA and how is it managed?
- Bell Palsy: AAN Guideline Diagnosis, Steroid Therapy, Antiviral Adjunct, Eye Care, and Recovery Prognosis
- Parkinson Disease: Clinical Diagnosis, Dopaminergic Therapy, and Advanced Therapy Options
- Huntington Disease: Diagnosis and Management
- Peripheral Neuropathy: Diagnosis, Workup, and Management
- Migraine: Diagnosis, Acute Treatment, and Preventive Therapy
- Wernicke Encephalopathy: Caine Criteria, IV Thiamine Dosing, and Korsakoff Prevention